|
1
|
Weber JS, O'Day S, Urba W, Powderly J,
Nichol G, Yellin M, Snively J and Hersh E: Phase I/II study of
ipilimumab for patients with metastatic melanoma. J Clin Oncol.
26:5950–5956. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hodi FS, O'Day SJ, McDermott DF, Weber RW,
Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel
JC, et al: Improved survival with ipilimumab in patients with
metastatic melanoma. N Engl J Med. 363:711–723. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Topalian SL, Hodi FS, Brahmer JR,
Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD,
Sosman JA, Atkins MB, et al: Safety, activity, and immune
correlates of anti-PD-1 antibody in cancer. N Engl J Med.
366:2443–2454. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ,
Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al:
Safety and activity of anti-PD-L1 antibody in patients with
advanced cancer. N Engl J Med. 366:2455–2465. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wolchok JD, Kluger H, Callahan MK, Postow
MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K,
et al: Nivolumab plus ipilimumab in advanced melanoma. N Engl J
Med. 369:122–133. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Couzin-Frankel J: Breakthrough of the year
2013. Cancer immunotherapy. Science. 342:1432–1433. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Snyder A, Makarov V, Merghoub T, Yuan J,
Zaretsky JM, Desrichard A, Walsh LA, Postow MA, Wong P, Ho TS, et
al: Genetic basis for clinical response to CTLA-4 blockade in
melanoma. N Engl J Med. 371:2189–2199. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Garon EB, Rizvi NA, Hui R, Leighl N,
Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L,
et al KEYNOTE-001 Investigators: Pembrolizumab for the treatment of
non-small-cell lung cancer. N Engl J Med. 372:2018–2028. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Reck M, Rodríguez-Abreu D, Robinson AG,
Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe
S, et al KEYNOTE-024 Investigators: Pembrolizumab versus
chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl
J Med. 375:1823–1833. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Le DT, Durham JN, Smith KN, Wang H,
Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, et
al: Mismatch repair deficiency predicts response of solid tumors to
PD-1 blockade. Science. 357:409–413. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dahlin AM, Henriksson ML, Van Guelpen B,
Stenling R, Öberg A, Rutegård J and Palmqvist R: Colorectal cancer
prognosis depends on T-cell infiltration and molecular
characteristics of the tumor. Mod Pathol. 24:671–682. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Llosa NJ, Cruise M, Tam A, Wicks EC,
Hechenbleikner EM, Taube JM, Blosser RL, Fan H, Wang H, Luber BS,
et al: The vigorous immune microenvironment of microsatellite
instable colon cancer is balanced by multiple counter-inhibitory
checkpoints. Cancer Discov. 5:43–51. 2015. View Article : Google Scholar :
|
|
13
|
Schalper KA, Brown J, Carvajal-Hausdorf D,
McLaughlin J, Velcheti V, Syrigos KN, Herbst RS and Rimm DL:
Objective measurement and clinical significance of TILs in
non-small cell lung cancer. J Natl Cancer Inst. 107:dju4352015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rooney MS, Shukla SA, Wu CJ, Getz G and
Hacohen N: Molecular and genetic properties of tumors associated
with local immune cytolytic activity. Cell. 160:48–61. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ock CY, Keam B, Kim S, Lee JS, Kim M, Kim
TM, Jeon YK, Kim DW, Chung DH and Heo DS: Pan-cancer immunogenic
perspective on the tumor microenvironment based on PD-L1 and CD8
T-cell infiltration. Clin Cancer Res. 22:2261–2270. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yamaguchi K, Urakami K, Nagashima T,
Shimoda Y, Ohnami S, Ohnami S, Ohshima K, Mochizuki T, Hatakeyama
K, Serizawa M, et al: Prevalence of low-penetrant germline TP53
D49H mutation in Japanese cancer patients. Biomed Res. 37:259–264.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ohshima K, Hatakeyama K, Nagashima T,
Watanabe Y, Kanto K, Doi Y, Ide T, Shimoda Y, Tanabe T, Ohnami S,
et al: Integrated analysis of gene expression and copy number
identified potential cancer driver genes with
amplification-dependent overexpression in 1,454 solid tumors. Sci
Rep. 7:6412017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Akiyama Y, Kondou R, Iizuka A, Ohshima K,
Urakami K, Nagashima T, Shimoda Y, Tanabe T, Ohnami S, Ohnami S, et
al: Immune response-associated gene analysis of 1,000 cancer
patients using whole-exome sequencing and gene expression
profiling-Project HOPE. Biomed Res. 37:233–242. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Brazma A, Hingamp P, Quackenbush J,
Sherlock G, Spellman P, Stoeckert C, Aach J, Ansorge W, Ball CA,
Causton HC, et al: Minimum information about a microarray
experiment (MIAME)-toward standards for microarray data. Nat Genet.
29:365–371. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Vogelstein B, Papadopoulos N, Velculescu
VE, Zhou S, Diaz LA Jr and Kinzler KW: Cancer genome landscapes.
Science. 339:1546–1558. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Papalexi E and Satija R: Single-cell RNA
sequencing to explore immune cell heterogeneity. Nat Rev Immunol.
18:35–45. 2018. View Article : Google Scholar
|
|
22
|
Teng MW, Ngiow SF, Ribas A and Smyth MJ:
Classifying cancers based on T-cell infiltration and PD-L1. Cancer
Res. 75:2139–2145. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tosolini M, Kirilovsky A, Mlecnik B,
Fredriksen T, Mauger S, Bindea G, Berger A, Bruneval P, Fridman WH,
Pagès F, et al: Clinical impact of different classes of
infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in
patients with colorectal cancer. Cancer Res. 71:1263–1271. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ascierto RA, Capone M, Urba WJ, Bifuco CB,
Botti G, Lugli A, Marincola FM, Ciliberto G, Galon J and Fox BA:
The additional facet of immunoscore: immunoprofiling as a possible
predictive tool for cancer treatment. J Transl Med. 11:542913.
View Article : Google Scholar
|
|
25
|
Lee HJ, Lee JJ, Song IH, Park IA, Kang J,
Yu JH, Ahn JH and Gong G: Prognostic and predictive value of
NanoString-based immune-related gene signatures in a neoadjuvant
setting of triple-negative breast cancer: Relationship to
tumor-infiltrating lymphocytes. Breast Cancer Res Treat.
151:619–627. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gnjatic S, Bronte V, Brunet LR, Butler MO,
Disis ML, Galon J, Hakansson LG, Hanks BA, Karanikas V, Khleif SN,
et al: Identifying baseline immune-related biomarkers to predict
clinical outcome of immunotherapy. J Immunother Cancer. 5:442017.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ayers M, Lunceford J, Nebozhyn M, Murphy
E, Loboda A, Kaufman DR, Albright A, Cheng JD, Kang SP, Shankaran
V, et al: IFN-γ-related mRNA profile predicts clinical response to
PD-1 blockade. J Clin Invest. 127:2930–2940. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Stroncek DF, Butterfield LH, Cannarile MA,
Dhodapkar MV, Greten TF, Grivel JC, Kaufman DR, Kong HH, Korangy F,
Lee PP, et al: Systematic evaluation of immune regulation and
modulation. J Immunother Cancer. 5:212017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Johnson DB, Frampton GM, Rioth MJ, Yusko
E, Xu Y, Guo X, Ennis RC, Fabrizio D, Chalmers ZR, Greenbowe J, et
al: Targeted next generation sequencing identifies markers of
response to PD-1 blockade. Cancer Immunol Res. 4:959–967. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dudley JC, Lin MT, Le DT and Eshleman JR:
Microsatellite instability as a biomarker for PD-1 blockade. Clin
Cancer Res. 22:813–820. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gong J, Wang C, Lee PP, Chu P and Fakih M:
Response to PD-1 blockade in microsatellite stable metastatic
colorectal cancer harboring a POLE mutation. J Natl Compr Canc
Netw. 15:142–147. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Prat A, Navarro A, Paré L, Reguart N,
Galván P, Pascual T, Martínez A, Nuciforo P, Comerma L, Alos L, et
al: Immune-related gene expression profiling after PD-1 blockade in
non-small cell lung carcinoma, head and neck squamous cell
carcinoma, and melanoma. Cancer Res. 77:3540–3550. 2017. View Article : Google Scholar : PubMed/NCBI
|
